All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Should antifungal prophylaxis be used in patients with AML who are treated with novel agents?

During the EHA2021 Virtual Congress, the AML Hub spoke with Jannik Stemler, University Hospital Cologne, Cologne, DE. We asked, Should antifungal prophylaxis be used in patients with AML who are treated with novel agents?

Should antifungal prophylaxis be used in patients with AML who are treated with novel agents?

In this video, Stemler discusses antifungal prophylaxis in adult patients with high risk AML treated with novel agents. He emphasizes the improvement in overall- and progression-free survival of patients that undergo intensive chemotherapy treatment in combination with antifungal therapy. Finally, Stemler touches upon drug-drug interactions, dosage, and the role of therapeutic monitoring.

Share:
More about...